+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Nerve growth factor inhibitors - Pipeline Insight, 2022

  • PDF Icon

    Drug Pipelines

  • 60 Pages
  • January 2022
  • Region: Global
  • DelveInsight
  • ID: 5526567
UP TO OFF until Dec 31st 2022
This “Nerve growth factor inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Nerve growth factor inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Nerve growth factor inhibitors Understanding

Nerve growth factor inhibitors: Overview


Nerve growth factor (NGF) is an insulin-like protein, which regulates growth, development and maintenance of sympathetic and embryonic sensory neurons.

Function - NGF is involved primarily in the growth, as well as the maintenance, proliferation, and survival of nerve cells (neurons). In fact, NGF is critical for the survival and maintenance of sympathetic and sensory neurons, as they undergo apoptosis in its absence. However, several recent studies suggest that NGF is also involved in pathways besides those regulating the life cycle of neurons.

Nerve growth factor inhibitors - NGF is involved in pain signalling. The exact role of NGF signalling in chronic pain is not fully understood, and multiple mechanisms are thought to be involved. NGF is released by immune cells in response to peripheral injury, and is thought to promote neural sensitisation, and neural sprouting. Elevated NGF levels are seen in those with chronic pain conditions (including interstitial cystitis, prostatitis, arthritis, pancreatitis, chronic headaches, cancer pain, and diabetic neuropathy, and injection of NGF causes allodynia and hyperalgesia. NGF inhibitors may take the form of monoclonal antibodies that bind to NGF, or small molecule inhibitors of NGF receptors. NGF inhibition may be achieved by sequestering free NGF molecules, blocking receptor binding, or inhibiting receptor function. Anti-NGF antibodies have demonstrated the greatest promise as potential medications.

Nerve growth factor inhibitors Emerging Drugs Chapters


This segment of the Nerve growth factor inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nerve growth factor inhibitors Emerging Drugs

Tanezumab: Eli Lilly and Company

Tanezumab is an investigational humanized monoclonal antibody, which works by selectively targeting, binding to and inhibiting NGF. NGF levels increase in the body as a result of injury, inflammation or in chronic pain states. By inhibiting NGF, tanezumab may help to keep pain signals produced by muscles, skin and organs from reaching the spinal cord and brain. Tanezumab has a novel mechanism that acts in a different manner than opioids and other analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs). Currently, it is in preregistration stage for the treatment of Musculoskeletal pain.

Fasinumab: Mirati Therapeutics

Fasinumab, a recombinant, fully human, selective anti-nerve growth factor (NGF) monoclonal antibody, is being developed by Regeneron Pharmaceuticals in collaboration with Mitsubishi Tanabe Pharma. Currently, it is in phase III stage of development for the treatment of Musculoskeletal pain.

Nerve growth factor inhibitors: Therapeutic Assessment


This segment of the report provides insights about the different Nerve growth factor inhibitors drugs segregated based on following parameters that define the scope of the report.

Major Players working on Nerve growth factor inhibitors


There are approx. 4+ key companies which are developing the Nerve growth factor inhibitors. The companies which have their Nerve growth factor inhibitors drug candidates in the most advanced stage, i.e. preregistration include, Eli Lilly and Company.

Phases


This report covers around 4+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Nerve growth factor inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nerve growth factor inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nerve growth factor inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nerve growth factor inhibitors drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Nerve growth factor inhibitors R&D. The therapies under development are focused on novel approaches for Nerve growth factor inhibitors.

Nerve growth factor inhibitors Report Insights

  • Nerve growth factor inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Nerve growth factor inhibitors Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions


Current Scenario and Emerging Therapies:

  • How many companies are developing Nerve growth factor inhibitors drugs?
  • How many Nerve growth factor inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Nerve growth factor inhibitors?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nerve growth factor inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Nerve growth factor inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Eli Lilly and Company
  • Mitsubishi Tanabe Pharma
  • Regeneron Pharmaceuticals
  • Spine Biopharma
  • Ensol Biosciences
  • Astellas Pharma

Key Products

  • Tanezumab
  • Fasinumab
  • YH 14618
  • Engedi 1000
  • ASP 6294

Table of Contents

IntroductionExecutive Summary
Nerve growth factor inhibitors: Overview
  • Structure
  • Mechanism of Action

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Nerve growth factor inhibitors - Analytical Perspective
In-depth Commercial Assessment
  • Nerve growth factor inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Nerve growth factor inhibitors Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Pre-registration)
  • Comparative Analysis

Tanezumab: Eli Lilly and Company
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

Engedi 1000: Ensol Biosciences
  • Product Description
  • Research and Development
  • Product Development Activities

Pre-clinical and Discovery Stage Products
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Nerve growth factor inhibitors Key CompaniesNerve growth factor inhibitors Key ProductsNerve growth factor inhibitors- Unmet NeedsNerve growth factor inhibitors- Market Drivers and BarriersNerve growth factor inhibitors- Future Perspectives and ConclusionNerve growth factor inhibitors Analyst ViewsNerve growth factor inhibitors Key CompaniesAppendix
List of Tables
Table 1 Total Products for Nerve growth factor inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Nerve growth factor inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Eli Lilly and Company
  • Mitsubishi Tanabe Pharma
  • Regeneron Pharmaceuticals
  • Spine Biopharma
  • Ensol Biosciences
  • Astellas Pharma